<DOC>
	<DOCNO>NCT00064337</DOCNO>
	<brief_summary>RATIONALE : Drugs use chemotherapy melphalan work different way stop cancer cell divide stop grow die . Combining chemotherapy donor peripheral stem cell transplantation may allow doctor give high dos chemotherapy drug kill cancer cell . PURPOSE : This phase II trial study well give melphalan together autologous stem cell transplantation work treat patient multiple myeloma primary systemic amyloidosis .</brief_summary>
	<brief_title>S0115 , High-Dose Melphalan Autologous Peripheral Stem Cell Transplantation Treating Patients With Multiple Myeloma Primary Systemic Amyloidosis</brief_title>
	<detailed_description>OBJECTIVES : - Determine overall survival patient high-risk multiple myeloma , primary systemic amyloidosis , light chain deposition disease treat two course modify high-dose melphalan autologous peripheral blood stem cell transplantation . - Determine hematologic response patient treat regimen . - Determine qualitative quantitative toxic effect regimen patient . - Determine prognostic significance cytogenetic marker patient . OUTLINE : This multicenter study . Patients stratify accord disease ( high-risk multiple myeloma v primary systemic amyloidosis v ) . - Induction therapy ( multiple myeloma patient ) : Patients receive oral dexamethasone day 1-4 , 9-12 , 17-20 oral thalidomide daily day 1-35 . Treatment repeat every 35 day 2 course absence disease progression unacceptable toxicity . - Mobilization stem cell collection : - Multiple myeloma patient : Within 28-35 day completion induction therapy , patient receive cyclophosphamide IV 2-3 hour day 1 filgrastim ( G-CSF ) subcutaneously ( SC ) daily begin day 2 continue day last leukapheresis . Usage mesna IV day 1 ( prior twice cyclophosphamide administration recommend ) . - Primary systemic amyloidosis patient : Patients receive G-CSF SC daily begin day 1 continue day last leukapheresis . All patient undergo leukapheresis collection stem cell target number CD34+ cell reach . - Conditioning regimen : Within 1-4 week mobilization , patient receive modify high-dose melphalan IV 20 minute day -2 . - Peripheral blood stem cell ( PBSC ) reinfusion : PBSCs reinfused day 0 . Patients receive G-CSF SC daily begin day 1 continue blood count recover . Patients undergo second autologous PBSC transplantation within 3-6 month , later 12 month , first transplantation . - Second conditioning regimen : Patients receive modify high-dose melphalan IV 20 minute day -2 . - Second PBSC infusion : PBSCs infuse day 0 . - Maintenance regimen ( multiple myeloma patient ) : Between 4-8 week second transplantation , patient progressive disease receive oral dexamethasone daily day 1-4 oral thalidomide daily day 1-28 . Courses repeat every 28 day 2 year absence disease progression unacceptable toxicity . Patients follow 3 6 month annually thereafter . PROJECTED ACCRUAL : A total 100 patient accrue study within 20-25 month .</detailed_description>
	<mesh_term>Multiple Myeloma</mesh_term>
	<mesh_term>Neoplasms , Plasma Cell</mesh_term>
	<mesh_term>Amyloidosis</mesh_term>
	<mesh_term>Dexamethasone acetate</mesh_term>
	<mesh_term>Dexamethasone</mesh_term>
	<mesh_term>Dexamethasone 21-phosphate</mesh_term>
	<mesh_term>Cyclophosphamide</mesh_term>
	<mesh_term>Melphalan</mesh_term>
	<mesh_term>Thalidomide</mesh_term>
	<mesh_term>BB 1101</mesh_term>
	<criteria>DISEASE CHARACTERISTICS : At least 1 follow diagnosis : Multiple myeloma Stage II III disease At least 1 follow must present : Serum Mprotein IgG , IgA , IgD , IgE great 1.0 g/dL Urinary Mprotein ( BenceJones ) least 200 mg/24 hour No IgM peak except patient physiologic criterion support diagnosis multiple myeloma ( e.g. , bony lesion , myeloma kidneycast nephropathy , absence adenopathy [ unless pathologyproven plasma cell infiltration ] ) No monoclonal gammopathy undetermined significance No indolent smolder myeloma No disease progression prior thalidomide dexamethasone Histologically confirm primary systemic amyloidosis No senile , secondary , localize , dialysisrelated , familial amyloidosis No severe cardiac involvement No preexertional syncope , ventricular arrhythmia , symptomatic pleural effusion associate cardiac involvement Light Chain Deposition Disease alone combination multiple myeloma meeting follow criterion : Deposition granular material contain free light chains/immunoglobulins bind Congo red Evidence plasma cell dyscrasia ( i.e. , monoclonal gammopathy serum urine immunofixation electrophoresis and/or clonal plasmacytosis ) bone marrow biopsy immunohistochemistry and/or elevate serumfree light chain concentration Must diagnose within past year Concurrent enrollment myeloma repository protocol SWOGS0309 must offer PATIENT CHARACTERISTICS : Age 18 ( patient amyloidosis OR patient amyloidosis multiple myeloma OR patient multiple myeloma poor renal function ) OR 70 ( patient multiple myeloma without poor renal function ) Performance status Zubrod 02 Life expectancy Not specify Hematopoietic Absolute neutrophil count least 1,000/mm^3 Platelet count least 100,000/mm^3 Hepatic Bilirubin great 2.5 time upper limit normal ( ULN ) SGOT SGPT great 2.5 time ULN Renal No hemodialysis within 2 hour melphalan stem cell infusion Cardiovascular See Disease Characteristics Hemodynamically stable ( i.e. , systolic blood pressure &gt; 90 mm Hg lie position within past 42 day ) No myocardial infarction within past 6 month No congestive heart failure No arrhythmia refractory medical therapy LVEF great 45 % echocardiogram MUGA Pulmonary See Disease Characteristics No history chronic obstructive chronic restrictive pulmonary disease Pulmonary function study ( e.g. , FEV_1 FVC ) least 50 % predict DLCO least 50 % predict Normal high resolution CT scan chest acceptable arterial blood gas ( i.e. , PO_2 great 70 ) require patient unable complete pulmonary function test due bone pain fracture Other Not pregnant nursing Negative pregnancy test Fertile patient must use effective contraception Multiple myeloma patient receive thalidomide must use 2 method effective contraception least 4 week , , least 4 week discontinuation thalidomide HIV negative No concurrent significant medical condition No concurrent uncontrolled lifethreatening infection No malignancy within past 5 year except adequately treat basal cell squamous cell skin cancer , carcinoma situ cervix , adequately treated stage I II cancer currently complete remission PRIOR CONCURRENT THERAPY : Biologic therapy See Disease Characteristics Chemotherapy See Disease Characteristics Prior cumulative melphalan dose 200 mg No concurrent chemotherapy Endocrine therapy See Disease Characteristics No concurrent hormonal therapy Radiotherapy No concurrent radiotherapy Surgery Not specify Other Recovered prior therapy Prior concurrent bisphosphonates allow</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>April 2015</verification_date>
	<keyword>primary systemic amyloidosis</keyword>
	<keyword>stage II multiple myeloma</keyword>
	<keyword>stage III multiple myeloma</keyword>
</DOC>